Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.13
NYSE:A's Cash-to-Debt is ranked lower than
64% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. NYSE:A: 1.13 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:A' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.63  Med: 1.33 Max: No Debt
Current: 1.13
Equity-to-Asset 0.55
NYSE:A's Equity-to-Asset is ranked lower than
58% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. NYSE:A: 0.55 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:A' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.5 Max: 0.71
Current: 0.55
0.31
0.71
Interest Coverage 9.00
NYSE:A's Interest Coverage is ranked lower than
67% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 54.16 vs. NYSE:A: 9.00 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:A' s Interest Coverage Range Over the Past 10 Years
Min: 0.53  Med: 6.44 Max: 12.45
Current: 9
0.53
12.45
Piotroski F-Score: 7
Altman Z-Score: 3.92
Beneish M-Score: -2.61
WACC vs ROIC
12.51%
14.43%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 15.70
NYSE:A's Operating Margin % is ranked higher than
84% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.88 vs. NYSE:A: 15.70 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:A' s Operating Margin % Range Over the Past 10 Years
Min: 1.05  Med: 11.85 Max: 16.32
Current: 15.7
1.05
16.32
Net Margin % 12.00
NYSE:A's Net Margin % is ranked higher than
86% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.64 vs. NYSE:A: 12.00 )
Ranked among companies with meaningful Net Margin % only.
NYSE:A' s Net Margin % Range Over the Past 10 Years
Min: -0.69  Med: 12.28 Max: 18.85
Current: 12
-0.69
18.85
ROE % 12.07
NYSE:A's ROE % is ranked higher than
74% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.95 vs. NYSE:A: 12.07 )
Ranked among companies with meaningful ROE % only.
NYSE:A' s ROE % Range Over the Past 10 Years
Min: -1.22  Med: 16.28 Max: 26.86
Current: 12.07
-1.22
26.86
ROA % 6.64
NYSE:A's ROA % is ranked higher than
75% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.53 vs. NYSE:A: 6.64 )
Ranked among companies with meaningful ROA % only.
NYSE:A' s ROA % Range Over the Past 10 Years
Min: -0.42  Med: 7.41 Max: 11.77
Current: 6.64
-0.42
11.77
ROC (Joel Greenblatt) % 61.02
NYSE:A's ROC (Joel Greenblatt) % is ranked higher than
85% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.23 vs. NYSE:A: 61.02 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:A' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 7.79  Med: 44.69 Max: 84.13
Current: 61.02
7.79
84.13
3-Year Revenue Growth Rate 4.20
NYSE:A's 3-Year Revenue Growth Rate is ranked higher than
51% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. NYSE:A: 4.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:A' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -22.9  Med: 3.05 Max: 18.4
Current: 4.2
-22.9
18.4
3-Year EBITDA Growth Rate 5.40
NYSE:A's 3-Year EBITDA Growth Rate is ranked higher than
61% of the 119 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. NYSE:A: 5.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:A' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -27.7  Med: 5.8 Max: 76.6
Current: 5.4
-27.7
76.6
3-Year EPS without NRI Growth Rate 29.10
NYSE:A's 3-Year EPS without NRI Growth Rate is ranked higher than
87% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. NYSE:A: 29.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:A' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -37.7  Med: 11.2 Max: 135.6
Current: 29.1
-37.7
135.6
GuruFocus has detected 6 Warning Signs with Agilent Technologies Inc $NYSE:A.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:A's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

A Guru Trades in Q1 2016

George Soros 42,800 sh (New)
Joel Greenblatt 11,573 sh (New)
Jim Simons 755,200 sh (+1473.33%)
Paul Tudor Jones 39,291 sh (+56.87%)
RS Investment Management 2,660,326 sh (+41.23%)
Mario Gabelli 202,300 sh (+9.59%)
Pioneer Investments 107,767 sh (+7.22%)
Chris Davis 72,389 sh (+2.07%)
PRIMECAP Management 5,172,590 sh (+0.85%)
Ron Baron 23,000 sh (unchged)
Keeley Asset Management Corp 105,819 sh (-11.27%)
Vanguard Health Care Fund 3,662,850 sh (-54.22%)
Steven Cohen 48,400 sh (-80.34%)
Eaton Vance Worldwide Health Sciences Fund 125,000 sh (-48.13%)
» More
Q2 2016

A Guru Trades in Q2 2016

Columbia Wanger 883,642 sh (New)
Stanley Druckenmiller 220,300 sh (New)
Joel Greenblatt 171,934 sh (+1385.65%)
Ron Baron 28,000 sh (+21.74%)
Steven Cohen 52,100 sh (+7.64%)
Pioneer Investments 107,767 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 125,000 sh (unchged)
George Soros Sold Out
Chris Davis Sold Out
PRIMECAP Management 5,018,630 sh (-2.98%)
Vanguard Health Care Fund 3,231,150 sh (-11.79%)
Mario Gabelli 172,400 sh (-14.78%)
RS Investment Management 2,149,542 sh (-19.20%)
Jim Simons 419,000 sh (-44.52%)
Paul Tudor Jones 9,330 sh (-76.25%)
Keeley Asset Management Corp 21,500 sh (-79.68%)
» More
Q3 2016

A Guru Trades in Q3 2016

Joel Greenblatt 470,942 sh (+173.91%)
Ron Baron 28,000 sh (unchged)
Stanley Druckenmiller 220,300 sh (unchged)
Pioneer Investments Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
Mario Gabelli 171,800 sh (-0.35%)
Keeley Asset Management Corp 21,385 sh (-0.53%)
Paul Tudor Jones 8,991 sh (-3.63%)
PRIMECAP Management 4,681,530 sh (-6.72%)
Columbia Wanger 703,334 sh (-20.41%)
Vanguard Health Care Fund 2,540,550 sh (-21.37%)
Steven Cohen 33,600 sh (-35.51%)
Jim Simons 12,400 sh (-97.04%)
» More
Q4 2016

A Guru Trades in Q4 2016

Jim Simons 766,200 sh (+6079.03%)
Steven Cohen 370,300 sh (+1002.08%)
Paul Tudor Jones 13,571 sh (+50.94%)
Keeley Asset Management Corp 24,025 sh (+12.35%)
Ron Baron 28,000 sh (unchged)
Stanley Druckenmiller Sold Out
PRIMECAP Management 4,654,830 sh (-0.57%)
Mario Gabelli 170,400 sh (-0.81%)
Columbia Wanger 588,093 sh (-16.38%)
Vanguard Health Care Fund 1,889,350 sh (-25.63%)
Joel Greenblatt 324,174 sh (-31.16%)
» More
» Details

Insider Trades

Latest Guru Trades with A

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334516    SIC: 3825
Compare:NYSE:Q, NYSE:LH, NYSE:DGX, NAS:IDXX, OTCPK:SSMXY, NAS:DXCM, NAS:QGEN, OTCPK:BMXMF, NYSE:PKI, NYSE:BIO.B, NAS:ICLR, NYSE:CRL, NAS:BRKR, NAS:PRAH, NAS:VWR, NYSE:ALR, NAS:PRXL, OTCPK:CZMWY, NAS:INCR, NAS:NEOG » details
Traded in other countries:AG8.Germany,
Agilent Technologies Inc provides application focused solutions that includes instruments, software, services and consumables for the entire laboratory workflow for life sciences, diagnostics and applied chemical markets.

Agilent Technologies Inc was incorporated in Delaware in May 1999. The Company provides application focused solutions that includes instruments, software, services and consumables for the entire laboratory workflow for life sciences, diagnostics and applied chemical markets. Its life sciences business, excluding the nucleic acid solutions division, together with the chemical analysis business combined to form a new segment called life sciences and applied markets business. Its diagnostics and genomics businesses combined with the nucleic acid solutions division from its life sciences business and became the diagnostics and genomics segment. Finally, the Agilent CrossLab segment was formed from the services and consumables businesses previously part of the life sciences and chemical analysis businesses. The Company's life sciences and applied markets business provides application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level. The diagnostics and genomics business is comprised of three areas of activity providing solutions that include reagents, instruments, software and consumables, which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab business spans the entire lab with its extensive consumables and services portfolio, which is designed to improve customer outcomes. In addition it conducts centralized order fulfillment and supply chain operations for businesses through the order fulfillment and supply chain organization (OFS). OFS provides resources for manufacturing, engineering and strategic sourcing to the Company's respective businesses. The life sciences and applied markets business focuses on The Pharmaceutical, Biotechnology, CRO & CMO Market; The Life Science Research Market; The Chemical & Energy Market; The Environmental & Forensics Market; and the Food Market. Its products fall into nine areas of work: liquid chromatography, gas chromatography, mass spectrometry, spectroscopy, software and informatics, lab automation and robotics, automated electrophoresis and microfluidics, vacuum technology and nuclear magnetic resonance systems. The diagnostics and genomics business includes the reagent partnership, pathology, companion diagnostics, genomics and the nucleic acid contract manufacturing businesses. The segment focuses on The Diagnostics and Clinical Market. The products under the segment fall into six areas of work: pathology products, specific proteins and flow reagents, target enrichment, cytogenetic research solutions and microarrays, PCR and qPCR instrumentation and molecular biology reagents and nucleic acid solutions. The Agilent CrossLab segment focuses on The Pha

Ratios

vs
industry
vs
history
PE Ratio 33.17
A's PE Ratio is ranked lower than
52% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.58 vs. A: 33.17 )
Ranked among companies with meaningful PE Ratio only.
A' s PE Ratio Range Over the Past 10 Years
Min: 2.75  Med: 15.05 Max: 48.52
Current: 33.17
2.75
48.52
Forward PE Ratio 24.15
A's Forward PE Ratio is ranked lower than
62% of the 45 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.46 vs. A: 24.15 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 33.17
A's PE Ratio without NRI is ranked lower than
52% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.65 vs. A: 33.17 )
Ranked among companies with meaningful PE Ratio without NRI only.
A' s PE Ratio without NRI Range Over the Past 10 Years
Min: 5.2  Med: 15.27 Max: 301.43
Current: 33.17
5.2
301.43
Price-to-Owner-Earnings 31.57
A's Price-to-Owner-Earnings is ranked lower than
51% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.11 vs. A: 31.57 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
A' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 2.5  Med: 15.53 Max: 194.42
Current: 31.57
2.5
194.42
PB Ratio 3.89
A's PB Ratio is ranked lower than
53% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.65 vs. A: 3.89 )
Ranked among companies with meaningful PB Ratio only.
A' s PB Ratio Range Over the Past 10 Years
Min: 1.22  Med: 2.62 Max: 3.89
Current: 3.89
1.22
3.89
PS Ratio 4.01
A's PS Ratio is ranked lower than
55% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.42 vs. A: 4.01 )
Ranked among companies with meaningful PS Ratio only.
A' s PS Ratio Range Over the Past 10 Years
Min: 0.6  Med: 1.91 Max: 7.61
Current: 4.01
0.6
7.61
Price-to-Free-Cash-Flow 25.28
A's Price-to-Free-Cash-Flow is ranked lower than
53% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.89 vs. A: 25.28 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
A' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.46  Med: 15.44 Max: 68.05
Current: 25.28
5.46
68.05
Price-to-Operating-Cash-Flow 21.09
A's Price-to-Operating-Cash-Flow is ranked lower than
62% of the 87 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.57 vs. A: 21.09 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
A' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.36  Med: 12.61 Max: 39.2
Current: 21.09
4.36
39.2
EV-to-EBIT 24.57
A's EV-to-EBIT is ranked lower than
51% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.83 vs. A: 24.57 )
Ranked among companies with meaningful EV-to-EBIT only.
A' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.9  Med: 14 Max: 249.8
Current: 24.57
4.9
249.8
EV-to-EBITDA 18.18
A's EV-to-EBITDA is ranked lower than
51% of the 112 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.07 vs. A: 18.18 )
Ranked among companies with meaningful EV-to-EBITDA only.
A' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4  Med: 11.2 Max: 31.7
Current: 18.18
4
31.7
Shiller PE Ratio 27.18
A's Shiller PE Ratio is ranked higher than
76% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 40.88 vs. A: 27.18 )
Ranked among companies with meaningful Shiller PE Ratio only.
A' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.84  Med: 18.96 Max: 45.85
Current: 27.18
9.84
45.85
Current Ratio 3.34
A's Current Ratio is ranked higher than
62% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. A: 3.34 )
Ranked among companies with meaningful Current Ratio only.
A' s Current Ratio Range Over the Past 10 Years
Min: 1.61  Med: 2.56 Max: 4.08
Current: 3.34
1.61
4.08
Quick Ratio 2.83
A's Quick Ratio is ranked higher than
61% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. A: 2.83 )
Ranked among companies with meaningful Quick Ratio only.
A' s Quick Ratio Range Over the Past 10 Years
Min: 1.04  Med: 2.06 Max: 3.44
Current: 2.83
1.04
3.44
Days Inventory 99.52
A's Days Inventory is ranked lower than
56% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.66 vs. A: 99.52 )
Ranked among companies with meaningful Days Inventory only.
A' s Days Inventory Range Over the Past 10 Years
Min: 91.25  Med: 98.82 Max: 191.04
Current: 99.52
91.25
191.04
Days Sales Outstanding 56.20
A's Days Sales Outstanding is ranked higher than
61% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.91 vs. A: 56.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
A' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.45  Med: 52.14 Max: 84.27
Current: 56.2
47.45
84.27
Days Payable 48.74
A's Days Payable is ranked lower than
55% of the 148 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 54.58 vs. A: 48.74 )
Ranked among companies with meaningful Days Payable only.
A' s Days Payable Range Over the Past 10 Years
Min: 43.61  Med: 51.45 Max: 79.36
Current: 48.74
43.61
79.36

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.93
A's Dividend Yield % is ranked lower than
58% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.11 vs. A: 0.93 )
Ranked among companies with meaningful Dividend Yield % only.
A' s Dividend Yield % Range Over the Past 10 Years
Min: 0.31  Med: 1.15 Max: 1.42
Current: 0.93
0.31
1.42
Dividend Payout Ratio 0.33
A's Dividend Payout Ratio is ranked higher than
95% of the 56 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.29 vs. A: 0.33 )
Ranked among companies with meaningful Dividend Payout Ratio only.
A' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.09  Med: 0.33 Max: 0.77
Current: 0.33
0.09
0.77
Forward Dividend Yield % 1.03
A's Forward Dividend Yield % is ranked lower than
54% of the 87 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.13 vs. A: 1.03 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.93
A's 5-Year Yield-on-Cost % is ranked lower than
68% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.65 vs. A: 0.93 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
A' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.31  Med: 1.15 Max: 1.42
Current: 0.93
0.31
1.42
3-Year Average Share Buyback Ratio 0.90
A's 3-Year Average Share Buyback Ratio is ranked higher than
90% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.20 vs. A: 0.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
A' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.5  Med: 1.05 Max: 11.4
Current: 0.9
-2.5
11.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 272.32
A's Price-to-Net-Current-Asset-Value is ranked lower than
99% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.95 vs. A: 272.32 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
A' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.8  Med: 11.57 Max: 1364
Current: 272.32
2.8
1364
Price-to-Tangible-Book 12.59
A's Price-to-Tangible-Book is ranked lower than
78% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.33 vs. A: 12.59 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
A' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.1  Med: 3.88 Max: 12.59
Current: 12.59
1.1
12.59
Price-to-Intrinsic-Value-Projected-FCF 1.56
A's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
60% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.11 vs. A: 1.56 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
A' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.61  Med: 1.19 Max: 2.86
Current: 1.56
0.61
2.86
Price-to-Median-PS-Value 2.09
A's Price-to-Median-PS-Value is ranked lower than
93% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.06 vs. A: 2.09 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
A' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.37  Med: 0.92 Max: 3.81
Current: 2.09
0.37
3.81
Price-to-Graham-Number 4.31
A's Price-to-Graham-Number is ranked lower than
65% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. A: 4.31 )
Ranked among companies with meaningful Price-to-Graham-Number only.
A' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.84  Med: 1.96 Max: 9.54
Current: 4.31
0.84
9.54
Earnings Yield (Greenblatt) % 4.07
A's Earnings Yield (Greenblatt) % is ranked higher than
77% of the 226 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. A: 4.07 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
A' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.4  Med: 7.15 Max: 20.2
Current: 4.07
0.4
20.2
Forward Rate of Return (Yacktman) % -7.17
A's Forward Rate of Return (Yacktman) % is ranked lower than
82% of the 56 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.41 vs. A: -7.17 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
A' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -10.2  Med: 8.2 Max: 78.6
Current: -7.17
-10.2
78.6

More Statistics

Revenue (TTM) (Mil) $4,241
EPS (TTM) $ 1.56
Beta1.47
Short Percentage of Float1.86%
52-Week Range $36.47 - 51.84
Shares Outstanding (Mil)322.06

Analyst Estimate

Oct17 Oct18 Oct19
Revenue (Mil $) 4,327 4,529 4,728
EPS ($) 2.12 2.36 2.72
EPS without NRI ($) 2.12 2.36 2.72
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.42%
Dividends per Share ($) 0.53 0.58 0.60
» More Articles for A

Headlines

Articles On GuruFocus.com
Agilent Technologies Raises Dividend 15% Dec 06 2016 
A Growth Stock in the Land of Value Stocks? Nov 30 2016 
A High-Tech Manufacturer With Excellent Growth Prospects Nov 03 2016 
Gurus Invest in Top Biotechnology Stocks Jun 20 2016 
Agilent, Apple and Canadian Pacific Are Among Larry Robbins' New Buys Dec 22 2015 
Should You Wait to Bet on Agilent Technologies? Dec 20 2015 
Larry Robbins Buys Cigna, Monsanto and Sells Out McDonald's Dec 09 2015 
Agilent Technologies Drop Means Buy Now Aug 27 2015 
Why Agilent Technologies is a "Hold" Jun 17 2015 
Buy the Keysight Technologies Spinoff After the Dip Jun 17 2015 

More From Other Websites
Agilent Technologies, Inc. : A-US: Dividend Analysis : January 03rd, 2017 (record date) : By the... Feb 24 2017
Agilent Technologies Announces Webcasts for Investment Community Feb 23 2017
Post Earnings Coverage as Agilent Revenue Gained 4%, Adjusted EPS Advanced 15% Feb 21 2017
Stocks Open Mixed; Will Bulls Stick Around For Another Day? Feb 15 2017
Agilent Technologies (A) Beats on Q1 Earnings & Revenues Feb 15 2017
Edited Transcript of A earnings conference call or presentation 14-Feb-17 9:30pm GMT Feb 15 2017
Agilent Technologies Inc Earnings Call scheduled for 4:30 pm ET today Feb 14 2017
AGILENT TECHNOLOGIES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 14 2017
Agilent beats Street 1Q forecasts Feb 14 2017
Agilent beats Street 1Q forecasts Feb 14 2017
Agilent Technologies Reports First-Quarter 2017 Results Feb 14 2017
Q1 2017 Agilent Technologies Inc Earnings Release - After Market Close Feb 14 2017
Electronics Stocks' Earnings Slated on Feb 14: A, GNRC, NVMI Feb 13 2017
Cigna: A Healthy Pick, Deal or No Deal Feb 10 2017
Can Agilent Technologies (A) Pull a Surprise in Q1 Earnings? Feb 10 2017
Agilent Technologies' Uptrend Is 'A'-mazing Feb 08 2017
Agilent (A) Announces Expanded Use of Diagnostic Assay (revised) Feb 06 2017
Agilent (A) Announces Expanded Use of Diagnostic Assay Feb 02 2017
[$$] Twist Bioscience Fires Back at Agilent Technologies Jan 31 2017
Agilent Technologies Expands Dako’s CE Marked PD-L1 IHC 22C3 pharmDx Companion Diagnostics Jan 31 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)